Ruxolitinib
Incyte
['derm', 'vitiligo']
a symposium at the 2023 annual meeting convened speakers who presented current data on the use of janus kinase (jak) inhibitors in dermatology, including in #atopicdermatitis and #vitiligo. #aad read now! 
The American Journal of #ManagedCare is a peer-reviewed, indexed publication. https://t.co/I2WRhmhOVC offers news in health policy, disease states, and managed care.